Prevention of Thromboembolism with Low-Molecular-Weight Heparin in Orthopedic Surgery: A 5-Year Experience

Clinical and Applied Thrombosis/Hemostasis

Volumn 10, Issue 1, 2004, Pages 1-4

  Wenzl, M E ^a,b   Hasse, W ^a   Seide, K ^a   Wolter, D ^a  

^a BG Trauma Hospital   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Diagnosis related incidences of DVT; Heparin induced thrombocytopenia; Low molecular weight heparin; Prevention of thromboembolism; Unfractionated heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; DANAPAROID; FRAGMIN P; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG INDUCED DISEASE; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; KNEE DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE TRAUMA; ORTHOPEDIC SURGERY; PHLEBOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TIBIA FRACTURE; TOTAL KNEE REPLACEMENT;

EID: 2142654335     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960401000101     Document Type: Article

References (13)

1. Turpie AG, Eriksson BI, Lassen MR, et al. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopedic surgery. J South Orthop Assoc 2002;11:182.
2. Kemkes-Matthes B. Hirudin for prophylaxis and treatment of deep vein thrombosis. Semin Thromb Hemost 2002; 28:455.
3. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288.
4. Haas S, Haas P. The efficacy of low molecular weight heparins-an overview. Semin Thromb Hemost 1993;19 (Suppl 1):101.
5. Leizorovicz A, Haugh MC, Chapuis FR, et al. Low molecular weight heparin in the prevention of perioperative thrombosis. BMJ 1992;305:913.
6. Nurmohamed MT, Rosendal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopedic surgery: A meta-analysis. Lancet 1992;340:152.
7. Hull RD, Pineo GF, Francis C, et al. Low-molecular-heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients. Arch Intern Med 2000;1600:2199.
8. Planes A, Samama MM, Lensing AW, Buller HR, et al. Prevention of deep vein thrombosis after hip replacement-comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999; 81(1):22.
9. Guidelines for prevention thromboembolism in surgery. German Society of Surgery, 2000
10. Nicolaides AN, Arcelus J, Belcaro G, et al. Prevention of venous thromboembolism. European Consensus Statement. IntAngiol 1992;11:151.
11. Blanchard J, Meuwly JY, Leyvraz PF, et al. Prevention of deep vein thrombosis after total knee replacement. J Bone Joint Surg 1999;81:654.
12. Eriksson BI, Kälebo P, Anthymr BA, et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. J Bone Joint Surg 1991;73:484.
13. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332(20):1330.